ABSTRACT

Objective: To describe in Mexican population, trends in national morbidity and mortality for pneumonia in adults from 1984 to 2010. Methods: An ecological study of retrospective time series from 1984 to 2010 for morbidity, and from 2000 to 2008 for pneumonia mortality using national data available. The percentage change in the number of cases and crude and age-adjusted rate was measured. The statistical significance of the annual trends was assessed with the nonparametric trend test for ordered groups. Results: Pneumonia was mainly in children aged 0-4 years and over 65 years old. Morbidity showed a signifi cant upward trend. Deaths were maintained without signifi cant trend observed; analysis by age group went down in all groups except in the 15 to 64 who observed an upward trend. Conclusions: The rising morbidity and overall mortality did not observe any trend, do assume that interventions to improve control of pneumonia are still inadequate, so it is essential to develop future research in Mexican population to identify areas of weakness and health policies needed to observe a favorable change.

KEYWORDS

Pneumonia, Mexico, morbidity, mortality, trends.

REFERENCES

1. World Health Organization. 2014. The 10 leading causes of death in the world, 2012. Fact sheet No. 310. Updated May 2014. Access date: August 14, 2012. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/ index.html

2. Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009;30(2):127-135. doi: 10.1055/s-0029-1202941.

3. Jokinen C, Heiskanen L, Juvonen H, et al. Incidencie of community-acquired pneumonia in the population of four municipalities in Eastern Finland. Am J Epidemiol 1993;137(3):977-988.

4. López AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global burden of the disease and risk factors. Capítulo 1: La medición de la carga mundial de morbilidad y de los factores de riesgo, 1990-2001. OMS. 1-15.

5. Secretaría de Salud. Anuarios de morbilidad de la Dirección General de Epidemiología. Fecha de consulta: 20 de septiembre, 2012. Accesible en: http://www.dgepi. salud.gob.mx/2010/plantilla/inicio_anuarios.html

6. Secretaría de Salud. Sistema Nacional de Información en Salud. Mortalidad. Información 2000-2008. Fecha de consulta: 30 de septiembre, 2012. Accesible en: http:// sinais.salud.gob.mx/mortalidad/

7. American Lung Association Research and Program Services Epidemiology and Statistics Unit April 2010. Trends in Pneumonia and Influenza Morbidity and Mortality.

8. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008;14(5):727-733. doi: 10.3201/eid1405.071011.

9. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005;294(21):2712-2719.

10. Ruhnke GW, Coca-Perraillon M, Kitch BT, Cutler DM. Marked reduction in 30-day mortality among elderly patients with community-acquired pneumonia. Am J Med 2011;124(2):171-178.e1. doi: 10.1016/j.amjmed. 2010.08.019.

11. Fine MJ, Auble TE, Tealy DM, et al. A prediction rule to identifiy low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-250.

12. Vila-Córcoles A, Ochoa-Gondar O, Hospital I, et al; EVAN Study Group. Protective effects of the 23-valente pneumococcal polysacharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006;43(7):860- 868.

13. Spaude KA, Abrutyn E, Kirchner C, Kim A, Daley J, Fisman DN. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med 2007;167(1):53-59.

14. García-García L, Valdespino-Gómez JL, Lazcano-Ponce E, et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study en Mexico City. BMJ 2009;339:b3928. doi: 10.1136/bmj.b3928.

15. Ruhnke GW, Coca-Perraillon M, Kitch BT, Cutler DM. Trends in mortality and medical spending in patients hospitalized for community-acquired pneumonia: 1993- 2005. Med Care 2010;48(12):1111-116. doi: 10.1097/ MLR.0b013e3181f38006.

16. Trejo-Valdivia B, Mendoza-Alvarado LR, Palma-Coca O, Hernández-Ávila M, Téllez-Rojo Solís MM. Encuesta Nacional de Cobertura de Vacunación (influenza, neumococo y tétanos) en adultos mayores de 60 años en México. Salud Pública Mex 2012;54(1):39-46.

17. Kuri-Morales P, Galván F, Cravioto P, Zárraga-Rosas LA, Tapia-Conyer R. Mortalidad en México por influenza y neumonía (1990-2005). Salud Pública Mex 2006;48(5):379-384.

18. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275(2):134-141.

19. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90(2):223-229.